Guidant reiterated by JMP at market perform

Guidant Corp. was reiterated by JMP Securities analyst Robert C. Faulkner at a market perform after Johnson & Johnson revised its offer to acquire Guidant for $68 a share. The Boston Scientific deal at $72 a share appears to require alterations in order to be fully workable for Guidant. JMP's Faulkner said he believes that adopting the J&J offer deprives Guidant shareholders of the opportunity to hold a superior equity. Shares of the Indianapolis medical device maker were down 4 cents, or 0.06%, at $70.40 on volume of 8,876,300 shares versus the three-month running average of 6,629,150 shares. (NYSE:GDT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.